Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) announced that CEO Abizer Gaslightwala will present in person at the 2026 Biocom Global Partnering & Investor Conference.

The presentation is scheduled for Wednesday, February 25, 2026 at 11:00 AM PST in Track B, and management will be available for one-on-one meetings with registered investors.

Key Figures

Conference presentation time: 11:00 AM PT, Feb 25, 2026 Conference dates: February 24–26, 2026 ADSs registered for resale: 34,680,906 ADSs +5 more

8 metrics

Conference presentation time 11:00 AM PT, Feb 25, 2026 Biocom Global Partnering & Investor Conference in-person talk

Conference dates February 24–26, 2026 Biocom Global Partnering & Investor Conference schedule

ADSs registered for resale 34,680,906 ADSs S-1 resale registration tied to warrants and financings

Potential warrant proceeds $8.9 million Maximum cash if related warrants exercised in full

Cash balance about $2.5 million Reported as of September 30, 2025 in S-1

ADSs outstanding 45,781,350 ADSs Outstanding as of January 22, 2026 per S-1

Registered direct offering size 10,043,774 ADSs ADSs sold at $0.3883 per ADS in Dec 2025

Gross proceeds from Dec 2025 offer $3,899,997 Registered direct offering before fees, Dec 17, 2025

Market Reality Check

Price: $0.2440 Vol: Volume 233,649 is below 2...

normal vol

$0.2440 Last Close

Volume Volume 233,649 is below 20-day average 302,048 (relative volume 0.77x). normal

Technical Shares at $0.244, well below 200-day MA of $0.80 and 85.9% under 52-week high.

Peers on Argus

AKTX was up 4.72% pre-news. Momentum scanner shows mixed peer action: PPCB and A...

2 Up 1 Down

AKTX was up 4.72% pre-news. Momentum scanner shows mixed peer action: PPCB and ALLR up, RNTX down, and sector flag set to false, indicating moves are more stock-specific than broad biotech rotation.

Common Catalyst Multiple small-cap biotech names, including AKTX and QTTB, are highlighting participation in investor conferences, suggesting an outreach/visibility theme rather than a single fundamental sector catalyst.

Historical Context

5 past events · Latest: Feb 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 11	Investor interview	Positive	+1.4%	CEO discussed expanded ADC pipeline and new AKTX-102 program.
Feb 05	Investor webinar	Positive	-2.2%	Corporate overview of ADC platform and timelines for AKTX-101/102.
Jan 26	Patent & pipeline	Positive	-0.5%	Filed key patent and unveiled AKTX-102 targeting CEACAM5 tumors.
Jan 09	CEO update	Positive	-0.3%	CEO Corner on 2025 progress and path to clinical transition.
Jan 08	Conference presentation	Positive	-1.7%	Announcement of in-person presentation at 2026 Biotech Showcase.

Pattern Detected

Recent positive corporate and pipeline updates often saw modest or negative next-day moves, with price diverging from upbeat operational news in 4 of the last 5 events.

Recent Company History

Over the past months, Akari emphasized its transition to oncology ADCs, highlighting the PH1 payload platform and lead candidate AKTX-101 alongside new program AKTX-102. Updates included a key patent filing, CEO communications on 2025 progress, and several investor presentations and webinars. Price reactions to these largely positive, visibility-focused announcements were mostly muted or negative, with 4 of 5 prior events showing declines despite constructive narratives. Today’s conference presentation fits this pattern of ongoing investor outreach rather than a discrete clinical or financial inflection.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-29

Akari has an active, effective S-3 shelf registration dated Jul 29, 2025, with reported remaining capacity of $72,500,000 and prior usage via 424B5 takedowns in October and December 2025. This structure provides flexibility to raise additional capital relatively quickly, subject to market conditions and shareholder approvals where required.

Market Pulse Summary

This announcement centers on Akari’s in-person presentation at a major partnering and investor confe...

Analysis

This announcement centers on Akari’s in-person presentation at a major partnering and investor conference, continuing a series of outreach events showcasing its ADC platform. Recent filings underscore both opportunity and risk: limited cash of about $2.5 million, reliance on warrant structures that could provide up to $8.9 million, and an effective S-3 shelf for additional capital raising. Investors watching this story typically track clinical progress for AKTX-101/102, financing developments, and Nasdaq listing compliance alongside these visibility efforts.

Key Terms

antibody drug conjugates, ADCs, immuno-oncology

3 terms

antibody drug conjugates medical

"an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

ADCs medical

"developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today"

Antibody-drug conjugates (ADCs) are targeted cancer medicines that combine an antibody, which seeks out specific markers on tumor cells, with a powerful drug payload that is released once the antibody binds its target. Think of them as a guided missile that delivers a toxic package directly to diseased cells to limit harm to healthy tissue. Investors watch ADC news closely because clinical trial results, manufacturing complexity and regulatory decisions can sharply change a biotech company’s value.

immuno-oncology medical

"developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

AI-generated analysis. Not financial advice.

In-person presentation on Wednesday, February 25th at 11:00 AM PT

TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will present at the 2026 Biocom Global Partnering & Investor Conference, being held February 24–26, 2026, at The Lodge at Torrey Pines in San Diego, CA.

Presentation details are as follows:
Date/Time: Wednesday, February 25, 2026, at 11:00 AM PST
Location: Track B

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website. 

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com   

FAQ

When will Akari Therapeutics (AKTX) present at the 2026 Biocom Global Partnering & Investor Conference?

The presentation is scheduled for Wednesday, February 25, 2026 at 11:00 AM PST. According to Akari Therapeutics, CEO Abizer Gaslightwala will deliver the in-person presentation in Track B and meet one-on-one with registered investors at the conference.

Where is Akari Therapeutics (AKTX) presenting during the Biocom 2026 conference?

Akari will present in Track B at the conference venue. According to Akari Therapeutics, the event runs February 24–26, 2026 at The Lodge at Torrey Pines in San Diego, with management available for in-person investor meetings.

Who from Akari Therapeutics (AKTX) will present at the Biocom Global Partnering & Investor Conference?

Abizer Gaslightwala, President and CEO, will present on behalf of Akari Therapeutics. According to Akari Therapeutics, he will present in person and management will be available for one-on-one meetings with qualified, registered investors.

Can investors meet Akari Therapeutics (AKTX) management at the 2026 Biocom conference?

Yes. Management will be available for in-person one-on-one meetings with qualified, registered investors. According to Akari Therapeutics, meetings require conference registration and are arranged during the February 24–26, 2026 event schedule.

How can investors get more information about Akari Therapeutics' (AKTX) Biocom 2026 presentation?

Investors should consult the conference website for details on schedule and registration. According to Akari Therapeutics, additional presentation and meeting information is available through the conference website for registered attendees.